AbbVie finalizes takeover of Nimble Therapeutics

ting the standard of care for individuals with autoimmune diseases.”

The acquisition of Nimble Therapeutics by AbbVie signifies a significant milestone in strengthening AbbVie’s pipeline and research and development capabilities. Through this acquisition, AbbVie gains access to Nimble’s innovative oral peptide IL23R inhibitor, currently in preclinical development for the treatment of psoriasis. Furthermore, Nimble’s peptide synthesis, screening, and optimization platform, utilizing proprietary technology, accelerates the discovery and optimization of oral peptide candidates for various targets.

Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research at AbbVie, expressed enthusiasm about the completion of the acquisition and the opportunity to enhance AbbVie’s immunology pipeline with Nimble’s novel oral peptide assets. Sedgwick highlighted the integration of Nimble’s proprietary technology into AbbVie’s research and development capabilities as a crucial step in advancing treatments for autoimmune diseases. The addition of Nimble’s talented team to AbbVie aligns with the company’s dedication to improving care standards for individuals with autoimmune conditions.

AbbVie’s mission revolves around discovering and delivering groundbreaking medicines and solutions to address prevalent health issues and future medical challenges. Focused on key therapeutic areas such as immunology, oncology, neuroscience, and eye care, AbbVie also offers a range of products and services through its Allergan Aesthetics portfolio. The completion of the Nimble Therapeutics acquisition aligns with AbbVie’s commitment to advancing research and development efforts in the field of immunology.

The forward-looking statements shared by AbbVie regarding the acquisition underline the company’s awareness of potential risks and uncertainties that may impact future outcomes. Factors such as intellectual property challenges, competition, research and development complexities, legal actions, and regulatory changes are crucial considerations in AbbVie’s strategic decisions. AbbVie’s transparency about these factors and its commitment to adapting to evolving circumstances demonstrate a proactive approach to managing risks.

In conclusion, the acquisition of Nimble Therapeutics by AbbVie represents a strategic move to enhance AbbVie’s immunology pipeline and research capabilities. By incorporating Nimble’s innovative oral peptide assets and proprietary technology, AbbVie aims to accelerate the development of treatments for autoimmune diseases. This partnership reflects AbbVie’s continued dedication to improving the lives of individuals impacted by autoimmune conditions through innovative solutions and advanced research initiatives.